EUVIMEDEUVIMED entdecken
Crossref

Targeting Dysregulated Epigenetic Modifiers With Kidney‐Targeted Nanotherapeutics for Polycystic Kidney Disease

Joshua Giblin, Rowan Simon, Jose Zarate-Diaz, Brenton Lee, Eun Ji Chung iD

Journal of Biomedical Materials Research Part A · 2025-04 · 113 (4)

DOI: 10.1002/jbm.a.37909 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Biomedical Materials Research Part A, online erschienen am 09.04.2025. Verfasst von Joshua Giblin und 4 weiteren Autor:innen. Beteiligte Einrichtung: Alfred E. Mann Department of Biomedical Engineering, University of Southern California, Los Angeles, California, USA. Hauptthemen laut MEDLINE: Epigenesis, Genetic, Polycystic Kidney, Autosomal Dominant, Kidney. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: This work was supported by the USC Research and Innovation (R&I) Alternative Methods to Animal Research grant awarded to E.J.C..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Autosomal dominant polycystic kidney disease (ADPKD) is the most common genetic kidney disease worldwide. The one small molecule drug available to patients, tolvaptan, is associated with off‐target side effects and high discontinuation rates, necessitating the development of new therapeutic strategies. Previous work has shown that the epigenome is altered in ADPKD; however, the identification and targeting of dysregulated epigenetic modulators has yet to be explored for human ADPKD therapy. Using cells derived from cysts of ADPKD patients, we tested the gene expression of several epigenetic modulators. We found Brd4 and BMi1 are upregulated and observed that their inhibition using small molecule drugs, AZD‐5153 and PTC‐209, significantly slowed the proliferation of ADPKD patient cells. To enhance the delivery of AZD‐5153 and PTC‐209 to renal cells, we loaded the drugs into kidney‐targeting micelles (KM) and assessed their therapeutic effects in vitro. Combining AZD‐5153 and PTC‐209 in KMs had a synergistic effect on reducing the proliferation in ADPKD patient cells and in a 3D PKD cyst model. These findings were also consistent in murine in vitro models using Pkd1 null renal proximal tubule cells. In summary, we demonstrate Brd4 and BMi1 as novel targets in ADPKD and targeting the epigenome using kidney nanomedicine as a novel therapeutic strategy in ADPKD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Epigenesis, GeneticPolycystic Kidney, Autosomal DominantKidneyHumansCell Cycle ProteinsCell ProliferationAnimalsTranscription FactorsNuclear ProteinsPolycomb Repressive Complex 1MiceCell LineBromodomain Containing Proteins

Stichwörter der Autor:innen

ADPKDchronic kidney diseasedrug deliveryepigeneticsnanomedicine

Substanzen

BRD4 protein, humanCell Cycle ProteinsTranscription FactorsNuclear ProteinsPolycomb Repressive Complex 1Bromodomain Containing Proteins

Autor:innen und Institutionen

  • Alfred E. Mann Department of Biomedical Engineering, University of Southern California, Los Angeles, California, USA.
  • Department of Medicine, Division of Nephrology and Hypertension, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
  • Department of Chemical Engineering and Materials Science, University of Southern California, Los Angeles, California, USA.
  • Department of Surgery, Division of Vascular Surgery and Endovascular Therapy, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
  • Department of Stem Cell Biology and Regenerative Medicine, University of Southern California, Los Angeles, California, USA.
  • Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California, USA.

ORCID-Profile: Eun Ji Chung

Förderung

  • This work was supported by the USC Research and Innovation (R&I) Alternative Methods to Animal Research grant awarded to E.J.C.

Zitieren

APA

Giblin, J., Simon, R., Zarate-Diaz, J., Lee, B., & Chung, E. J. (2025). Targeting Dysregulated Epigenetic Modifiers With Kidney‐Targeted Nanotherapeutics for Polycystic Kidney Disease. Journal of Biomedical Materials Research Part A, 113(4). https://doi.org/10.1002/jbm.a.37909

Vancouver

Giblin J, Simon R, Zarate-Diaz J, Lee B, Chung EJ. Targeting Dysregulated Epigenetic Modifiers With Kidney‐Targeted Nanotherapeutics for Polycystic Kidney Disease. Journal of Biomedical Materials Research Part A. 2025;113(4). doi:10.1002/jbm.a.37909

BibTeX
@article{Giblin2025,
  author = {Giblin, Joshua and Simon, Rowan and Zarate-Diaz, Jose and Lee, Brenton and Chung, Eun Ji},
  title = {Targeting Dysregulated Epigenetic Modifiers With Kidney‐Targeted Nanotherapeutics for Polycystic Kidney Disease},
  journal = {Journal of Biomedical Materials Research Part A},
  year = {2025},
  volume = {113},
  number = {4},
  doi = {10.1002/jbm.a.37909}
}
Kostenlos starten →